Market Place
Sourcing Support
Flagship-founded Evelo finds dissolution is only viable option
22 Nov 2023 //
FIERCE BIOTECH
Evelo Announces Top-Line Results From its Phase 2 Clinical Study with EDP2939
17 Oct 2023 //
GLOBENEWSWIRE
Evelo Biosciences Announces Second Quarter Financial Results
14 Aug 2023 //
GLOBENEWSWIRE
Circling Back On Evelo Biosciences
04 Aug 2023 //
SEEKING ALPHA
Evelo Biosciences enters into termination and surrender pact with Bio-Rad
21 Jul 2023 //
SEEKING ALPHA
Moderna Co-Founder`s Firm Bought Up This Embattled Biotech Stock
18 Jul 2023 //
BARRONS
Evelo Biosciences Closes $25.5 Million Private Placement
12 Jul 2023 //
GLOBENEWSWIRE
Evelo Biosciences Announces $25.5 Million Private Placement
10 Jul 2023 //
GLOBENEWSWIRE
Evelo Biosciences Announces Reverse Stock Split Effective
29 Jun 2023 //
GLOBENEWSWIRE
Evelo Biosciences Provides Clinical Updates
26 Apr 2023 //
GLOBENEWSWIRE
Evelo Biosciences Announces Fourth Quarter and Full Year 2022 Financial Results
16 Mar 2023 //
GLOBENEWSWIRE
Evelo to Report Fourth Quarter and Full Year 2022 Financial Results
09 Mar 2023 //
GLOBENEWSWIRE
Evelo Biosciences to Participate in the Cowen 43rd Annual Health Care Conference
01 Mar 2023 //
GLOBENEWSWIRE
Evelo Reports that EDP2939, First Oral Extracellular Vesicle Product Candidate
27 Feb 2023 //
GLOBENEWSWIRE
Evelo Biosciences Provides Clinical and Business Updates
01 Feb 2023 //
GLOBENEWSWIRE
Evelo keeps CEO, lets go of 48 employees after ph. 2 fail
01 Feb 2023 //
FIERCE BIOTECH
Evelo Biosciences Announces $45 Million Loan Agreement with Horizon Technology
16 Dec 2022 //
GLOBENEWSWIRE
Evelo Bio Announces Publication of Scientific Basis for SINTAX Medicines
15 Nov 2022 //
GLOBENEWSWIRE
Evelo Biosciences Reports 3Q 2022 Financial Results and Business Highlights
14 Nov 2022 //
GLOBENEWSWIRE
Evelo Biosciences Presents Biomarker Data Anti-inflammatory Effects of EDP1815
07 Sep 2022 //
GLOBENEWSWIRE
Evelo Biosciences to Participate in Morgan Stanley 20th Annual Global Health
01 Sep 2022 //
GLOBENEWSWIRE
Evelo Biosciences Announces Grant of Inducement Award
01 Sep 2022 //
GLOBENEWSWIRE
Evelo Biosciences Announces Succession Plan
11 Aug 2022 //
GLOBENEWSWIRE
Evelo Biosciences Announces Q2 2022 Rusult and Business Highlights
11 Aug 2022 //
GLOBENEWSWIRE
Evelo Biosciences to Announce Second Quarter 2022 Financial Results
05 Aug 2022 //
GLOBENEWSWIRE
Evelo Biosciences Apoints Marella Thorell as Chief Financial Officer
18 Jul 2022 //
GLOBENEWSWIRE
Evelo Biosciences Announces $79.2M Registered Direct Offering of Common Stock
25 May 2022 //
GLOBENEWSWIRE
While down 87% YOY, Evelo gets Flagship and others to infuse new capital
25 May 2022 //
ENDPTS
Evelo Biosciences Announces First Quarter 2022 Financial Results
12 May 2022 //
GLOBENEWSWIRE
Evelo Bio Appoints John Maraganore and Tassos Gianakakos as Strategic Advisors
21 Apr 2022 //
GLOBENEWSWIRE
Evelo Biosciences names former Alnylam, MyoKardia CEOs as strategic advisors
21 Apr 2022 //
GLOBENEWSWIRE
Evelo Biosciences pauses dermatitis drug after trail failure
15 Apr 2022 //
FIERCEBIOTECH
Evelo Bio Presents Data from Phase 2 Trial of EDP1815 in Psoriasis at 2022 AAD
28 Mar 2022 //
GLOBENEWSWIRE
Evelo Biosciences Announces Q4 and Full Year 2021 Financial Results
24 Mar 2022 //
GLOBENEWSWIRE
Evelo Bio to Report Q4 and FY 2021 Financial Results
17 Mar 2022 //
GLOBENEWSWIRE
Evelo Bio to Host KOL Discussion on Psoriasis and SINTAX Medicines
07 Mar 2022 //
GLOBENEWSWIRE
Evelo Biosciences to Participate in Cowen 42nd Annual Health Care Conference
02 Mar 2022 //
GLOBENEWSWIRE
Evelo Bio Begins Dosing in Phase 2 Trial of EDP1815 in Atopic Dermatitis
17 Feb 2022 //
GLOBENEWSWIRE
Evelo Bio Announces Significant Reductions in EDP1815 Phase 2 Psoriasis Trial
07 Feb 2022 //
GLOBENEWSWIRE
Evelo Biosciences Presents Data on EDP1815 MOA and Clinical Development
17 Jan 2022 //
GLOBENEWSWIRE
Evelo Biosciences Added to Nasdaq Biotechnology Index
14 Dec 2021 //
GLOBENEWSWIRE
Evelo Biosciences Presents Preclinical Data for EDP1867
13 Oct 2021 //
GLOBENEWSWIRE
Evelo Bio shares down 4% despite positive phase 2 psoriasis data
27 Sep 2021 //
SEEKINGALPHA
Evelo touts PhII win; Innovent, AnHeart claim interim PhII success
27 Sep 2021 //
ENDPTS
Evelo Announces Positive Phase 2 Clinical Data with EDP1815 in Psoriasis
27 Sep 2021 //
GLOBENEWSWIRE
Evelo Biosciences to Present at 2021 Cantor Global Healthcare Conference
20 Sep 2021 //
GLOBENEWSWIRE
Evelo Announces Issuance of U.S. Patent for Single Strains Bacteria
09 Sep 2021 //
GLOBENEWSWIRE
Evelo Biosciences Appoints Iain McInnes, M.B.Ch.B, Ph.D, to Board of Directors
07 Sep 2021 //
GLOBENEWSWIRE
Evelo BioSciences down 14% ahead of psoriasis candidate EDP1815 data readout
03 Sep 2021 //
SEEKINGALPHA
Evelo Biosciences Second Quarter 2021 Financial Results and Business Highlights
29 Jul 2021 //
GLOBENEWSWIRE
Evelo Report Second Quarter 2021 Financial Results on Thursday, July 29, 2021
22 Jul 2021 //
GLOBENEWSWIRE
Evelo Report Second Quarter 2021 Financial Results on Thursday, July 29, 2021
22 Jul 2021 //
GLOBENEWSWIRE
Evelo Biosciences Announces Grant of Inducement Award
14 Jul 2021 //
GLOBENEWSWIRE
Evelo Presents Further Positive Data from Phase 1b Clinical Trial of EDP1815
21 Apr 2021 //
GLOBENEWSWIRE
Evelo Presents Further Positive Data from Phase 1b Clinical Trial of EDP1815
20 Apr 2021 //
GLOBENEWSWIRE
Evelo Biosciences & Abdul Latif Jameel Health Announce Strategic Collaboration
23 Mar 2021 //
GLOBENEWSWIRE
Evelo Biosciences Announces Pricing of Public Offering of Common Stock
28 Jan 2021 //
GLOBENEWSWIRE
Evelo Biosciences Announces Proposed Public Offering of Common Stock
28 Jan 2021 //
GLOBENEWSWIRE
Evelo Reports New Positive Confirmatory Data from Phase 1b Trial of EDP1815
20 Jan 2021 //
GLOBENEWSWIRE
Sage Provides 2021 Corporate Strategy Update at J.P. Morgan
07 Jan 2021 //
BUSINESSWIRE
